In this retrospective study of 718 patients with advanced NSCLC and PDL1 TPS ≥ 50% treated with first-line pembrolizumab, there was no OS difference when the pembrolizumab dosing schedule was Q3W compared to Q6W demonstrated in multivariate analysis, including age, sex and PS. The gene discussed is CD274; the disease is non-small cell lung carcinoma.